Zamknij menu
Preface to the Fifth Edition - Stahl's Essential Psychopharmacology
A base anatômica dos transtornos mentais. psicofarmacologia stahl 5 edi%C3%A7%C3%A3o pdf gr%C3%A1tis
: The official publisher for the English 5th edition, offering digital and hardback options. Preface to the Fifth Edition - Stahl's Essential
| Chapter | Drug Class | Notable Updates in 5th ed. | |---------|------------|---------------------------| | 5 | | Re‑emphasis on when to consider TCAs in treatment‑resistant depression; safety checklist for MAOIs. | | 6 | SSRIs & SNRIs | New data on escitalopram, duloxetine, venlafaxine XR; discussion of sexual dysfunction mitigation strategies. | | 7 | Atypical Antidepressants (Bupropion, Mirtazapine, Vortioxetine) | Vortioxetine’s multimodal action & cognitive benefits. | | 8 | Mood Stabilizers – Lithium | Updated lithium‑nephrotoxicity monitoring protocol; pharmacogenomic considerations. | | 9 | Anticonvulsant Mood Stabilizers | Lamotrigine, valproate, carbamazepine, topiramate – comparative efficacy tables for bipolar I/II. | |10 | First‑Generation Antipsychotics | Revised EPS risk calculator; focus on long‑acting injectable (LAI) formulations. | |11 | Second‑Generation Antipsychotics | New agents (brexpiprazole, cariprazine) and deeper discussion on metabolic risk mitigation. | |12 | Third‑Generation/Partial Agonists | Mechanistic deep dive into aripiprazole, cariprazine, brexpiprazole – functional selectivity explained. | |13 | Anxiolytics – Benzodiazepines | Updated safety profile, dependence risk, and tapering algorithms. | |14 | Non‑benzodiazepine Anxiolytics (Buspirone, Hydroxyzine) | Clinical decision tree for anxiety subtypes. | |15 | Stimulants & Non‑stimulant ADHD Meds | New data on lisdexamfetamine, guanfacine XR, and viloxazine. | |16 | Sedative‑hypnotics | Review of zolpidem, eszopiclone, and emerging orexin antagonists (suvorexant). | |17 | Cognitive Enhancers & Alzheimer’s Agents | Donepezil, rivastigmine, memantine, and investigational agents (e.g., aducanumab) – brief neuro‑ethical commentary. | |18 | Substance‑Use Disorder Pharmacotherapies | Naltrexone, acamprosate, disulfiram, buprenorphine, and extended‑release formulations. | | | 8 | Mood Stabilizers – Lithium